Immunocore reports positive Phase 1 data for brenetafusp in ovarian cancer at ESMO 2024

Immunocore Holdings plc

Phase 1 monotherapy: 58% disease control, 6.5% RECIST response rate, median PFS 3.3 months in heavily pre-treated platinum-resistant ovarian cancer.
Phase 1 combo with chemo: 23% RECIST response rate, 69% disease control, 82% ctDNA molecular response rate.
T cell fitness signature associated with OS (28 vs 11 months) and PFS (5 vs 2 months) for KIMMTRAK in uveal melanoma, across ImmTAC platform.
Brenetafusp well tolerated; no treatment-related discontinuations; cytokine release syndrome manageable (57% Grade 1).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.